Edaravone dexborneol provides neuroprotective benefits by suppressing ferroptosis in experimental intracerebral hemorrhage

• Published in: Scientific reports Vol. 15; no. 1; pp. 16595 - 17
• Main Authors: Li, Han, Li, Xiang, Li, Mingzhi, Li, Wenxin, Wei, Jinghui, Huang, Yuming, Yan, Haiqing, Lin, Juntang, Zhang, Ping
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 13.05.2025; Nature Publishing Group; Nature Portfolio
• Subjects: 4-Hydroxynonenal; 631/154/556; 631/378/1934; Animal behavior; Animals; Antioxidants; Brain injury; Cerebral Hemorrhage - drug therapy; Cerebral Hemorrhage - metabolism; Cerebral Hemorrhage - pathology; Cerebral infarction; Disease Models, Animal; Edaravone - pharmacology; Edaravone dexborneol; Ferroptosis; Ferroptosis - drug effects; GPX4; Hematoma; Hemorrhage; Humanities and Social Sciences; Intracerebral hemorrhage; Iron; Magnetic resonance imaging; Male; Malondialdehyde; Molecular modelling; multidisciplinary; Neuroimaging; Neuroprotection; Neuroprotective Agents - pharmacology; Oxidants; Oxidizing agents; P53; p53 Protein; Phospholipid Hydroperoxide Glutathione Peroxidase - genetics; Phospholipid Hydroperoxide Glutathione Peroxidase - metabolism; Rats; Rats, Sprague-Dawley; Science; Science (multidisciplinary); Signal Transduction - drug effects; Stroke; Tumor Suppressor Protein p53 - metabolism; Ferroptosis; GPX4; Edaravone dexborneol; Intracerebral hemorrhage; P53

Edaravone dexborneol (EDB) is widely recognized for its anti-inflammatory and antioxidant properties and is clinically applied in the treatment of acute cerebral infarction. Ferroptosis is a critical process in the pathophysiology of brain injury following intracerebral hemorrhage (ICH). However, it...